Business Context and Reporting Period
Company: Gossamer Bio, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2018
Business Overview: Gossamer Bio is a clinical-stage biopharmaceutical company focused on immunology, inflammation, and oncology. The company operates with six programs: three clinical-stage candidates (GB001, GB002, GB004) and three preclinical programs. As of the reporting date, the company had no product revenue and was funded primarily through equity financings.
Key Financial Metrics
| Metric | 2018 | 2017 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(147.0) million | $(6.8) million |
| Operating Expenses | $149.0 million | $6.7 million |
| Cash, Cash Equivalents, and Marketable Securities | $228.7 million | $0.3 million |
| Accumulated Deficit | $(153.9) million | $(6.9) million |
| Working Capital | $211.6 million | $(0.8) million |
Note: All figures in millions unless otherwise noted. The company reported no debt outstanding as of December 31, 2018.
Material Changes vs. Prior Period
- Expense Surge: Total operating expenses increased by approximately $142.3 million year-over-year, driven by the acquisition of assets and the acceleration of clinical development.
- Research & Development (R&D): R&D expenses jumped from $0.9 million in 2017 to $55.3 million in 2018. This increase was primarily due to costs associated with GB001 ($23.4 million), GB002 ($16.0 million), and GB004 ($6.7 million).
- In-Process R&D (IPR&D): IPR&D expenses rose from $5.5 million to $49.7 million. This was largely attributable to upfront payments for the in-license of GB004 ($20.0 million), the acquisition of GB001 (stock issuance valued at $19.1 million), and the acquisition of GB1275 ($7.5 million).
- General & Administrative (G&A): G&A expenses increased from $0.3 million to $44.1 million, primarily driven by $30.3 million in stock-based compensation costs.
- Liquidity Position: Cash and marketable securities increased significantly from $0.3 million to $228.7 million following Series A and Series B preferred stock financings totaling approximately $303 million in gross proceeds during 2018.
Guidance, Outlook, and Risks
Management Commentary and Outlook
- Clinical Milestones: The company commenced a Phase 2b trial for GB001 (eosinophilic asthma) in October 2018, with an interim analysis expected in the first half of 2020. Phase 1b trials for GB002 (PAH) and GB004 (UC) are planned for the first half of 2019.
- Capital Requirements: Management believes existing cash resources will fund operations for at least the next 12 months from the filing date. However, the company expects to incur significant losses for the foreseeable future and will require substantial additional financing to complete clinical trials and commercialize products.
- Profitability: The company has not generated revenue and does not expect to do so until regulatory approval is obtained, which is years away. Profitability is not expected in the near term.
Risks and Contingencies
- Clinical Trial Failure: There is a high risk that product candidates will fail to demonstrate safety or efficacy in later-stage trials. Specifically, a prior Phase 2 trial for GB001 failed to meet its primary endpoint, though the company attributes this to study design issues.
- Regulatory Uncertainty: Approval by the FDA and other agencies is not guaranteed. Delays in regulatory review or requirements for additional trials could materially impact the business.
- Third-Party Reliance: The company relies entirely on third-party manufacturers for clinical supplies and CROs for clinical trials, creating risks related to supply chain and data integrity.
- Intellectual Property: Success depends on maintaining patent protection and avoiding infringement claims. Some IP is licensed from third parties (Pulmokine, Aerpio), creating dependency on licensors.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $228.7 million cash balance against the projected burn rate for the ongoing Phase 2b trial of GB001 and planned Phase 1b trials for GB002 and GB004.
- GB001 Trial Design: Review the specific design changes in the ongoing Phase 2b trial intended to address the failures of the previous Phase 2 trial (e.g., patient selection, eosinophil thresholds).
- Licensing Obligations: Assess the magnitude of future contingent milestone payments owed to Pulmokine (up to $298 million total) and Aerpio (up to $420 million total) upon regulatory and commercial success.
- Stock-Based Compensation: Monitor the impact of stock-based compensation on future operating expenses, which was $30.9 million in 2018.
- Post-IPO Liquidity: Note that the company completed an IPO in February 2019 (post-period) raising $291.5 million in net proceeds, which significantly alters the liquidity picture presented in the 2018 balance sheet.